Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer

Official Title

A Randomized, Multicentre, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Summary:

A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery)chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer.

Trial Description

Primary Outcome:

  • Pathological Complete response (pCR) Pathological Complete response (pCR) Using the definition of ypT0/is ypN0
  • Event-Free Survival (EFS)
Secondary Outcome:
  • Overall Survival (OS)
  • Disease-free Survival (DFS)
  • Distant Metastasis-free survival (DMFS)
  • Pathological Complete Response (pCR) using the definition of ypT0 ypN0
  • Pathological Complete Response (pCR) rate using the definition of ypT0/is
  • Objective response rate (ORR) using definition of tumour response rate per radiologic-based assessment
  • Objective response rate (ORR) using definition of tumour response rate per clinic-based physical assessment
  • Residual cancer burden (RCB) category status (0, I, II, III)
  • Incidence of adverse events (AEs)
  • Severity of adverse events (AEs)
  • Change from baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status/quality of life (QOL) subscale (items 29 and 30)
  • Change from baseline on the EORTC QLQ-C30 physical functioning subscale (items 1 to 5)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society